---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088345"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:09:24.835367+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4

## Summary
- Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.
- Net loss reduced to $3.4M ($0.17/sh) from $8.4M ($0.46/sh) in Q2 2023.
- Adjusted EBITDA positive $0.3M vs negative $0.6M in prior-year quarter.
- DFD-29 NDA for rosacea under FDA review with PDUFA goal date November 4, 2024.
- Appointed Joseph M. Benesch as permanent CFO and Michael C. Pearce to Board of Directors.

## SEC filing metadata
- accession: 0001104659-24-088345
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465924088345/0001104659-24-088345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465924088345/tm2421334d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088345
- JSON: https://secwatch.observer/filing/0001104659-24-088345.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.